Low-Dose Amphetamine Salts and Adult Attention-Deficit/Hyperactivity Disorder
J Clin Psychiatry 2000;61:414-417
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Effective treatments for
attention-deficit/hyperactivity disorder (ADHD) in adults are
still being defined. Pediatric studies have suggested that a
mixed amphetamine salt product (Adderall) is safe and effective
in the treatment of childhood forms of ADHD. Presently, there are
no reports in the scientific literature concerning the safety and
efficacy of Adderall in adults with ADHD, which is the focus of
Method: Twenty-four outpatients (mean age = 33.3
years) with DSM-IV ADHD were administered Adderall in an
open-label fashion, starting at 5 mg p.o. b.i.d., with titration
according to clinical response, across a 16-week period.
Relatives or spouses of each patient completed serial checklists
(including the Copeland Symptom Checklist and the Brown
Attention-Deficit Disorder Scales). Prospectively collected data
were analyzed retrospectively.
Results: Thirteen patients (54%) responded in a
positive manner to Adderall, based on Clinical Global
Impressions-Improvement scale scores. The mean end dose for
responders was 10.77 mg/day (0.14 mg/kg/day). An intent-to-treat
analysis revealed a decrease in the mean Copeland score from
99.05 to 63.3 (p < .001), while the mean Brown score dropped
from 76.75 to 50.85 (p < .0001). Nine patients (38%) were poor
responders or nonresponders to Adderall. Acute anxiety symptoms
occurred in 4 of 7 patients with a comorbid anxiety diagnosis.
Conclusion: Adderall may be an effective agent
for the treatment of adult forms of ADHD, with positive responses
occurring at relatively low doses, at least for some individuals.
However, Adderall may precipitate anxiety in vulnerable
individuals. Further study is required.